Ines Pires da Silva, Judith M. Versluis, Tasnia Ahmed, Douglas Buckner Johnson, Jennifer Soon, Clara Allayous, Camille L. Gerard, Joanna Mangana, Oliver Klein, Lisa Zimmer, Caroline Robert, Maria Grazia Vitale, Hui-Ling Yeoh, Olivier Michielin, Celeste Lebbe, Shahneen K. Sandhu, Christian U. Blank, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long
Research from MIA’s Medical Oncologist Dr Ines Silva and her team focussed on patients whose disease progressed after first being treated with combination immunotherapy – drugs that stimulate immune cells to fight cancer. Although around half of these patients are still alive five years after starting treatment, the majority of patients will progress and may require further treatment.
Florentia Dimitriou, Sabrina Hogan, Phil F. Cheng, Reinhard Dummer, Alexander M. Menzies, Georgina V. Long
Treatment of melanoma with immunotherapy can be lifesaving; however, it can also be complicated by significant side effects as the activated immune system cells may attack healthy cells as well. Immune cells communicate by producing small proteins, called ‘cytokines’, which co-ordinate the body’s response against inflammation. Medical Oncologist Dr Florentia Dimitriou and colleagues identified a cytokine, known as IL-6, which is increased in many inflammatory conditions.
Prachi Bhave, Angela Hong, Rebecca Johnson, Alexander M Menzies, Georgina V Long, Joanna Mangana, Douglas B Johnson, Zeynep Eroglu, Ozgecan Dulgar, Hui-Ling Yeoh, Andrew M Haydon, Georg Lodde, Elisabeth Livingstone, Adnan Khattak, Katharina Kahler, Axel Hauschild, Wei Wang, Matteo S Carlino
In an era where immunotherapy is now often given to reduce recurrence after surgery, Medical Oncologist Dr Prachi Bhave and colleagues at MIA investigated whether adjuvant radiotherapy is still effective in reducing melanoma recurrence. The study found that radiotherapy significantly reduced the risk of melanoma returning in nearby lymph nodes, and therefore continues to have a role in some patients whose melanoma has returned despite receiving immunotherapy after surgery.
Rebecca Johnson, Victoria Atkinson, Prachi Bhave, Alison M. Weppler, Geoffrey David Peters, Afaf Abed, Megan Lyle, Muhammad Adnan Khattak, Andrew Mark Haydon, Matteo S. Carlino, Shahneen Kaur Sandhu, Georgina V. Long, Alexander M. Menzies
Immunotherapy after surgery for Stage III melanoma has become the standard treatment approach. This research aimed to understand who is being treated with immunotherapy across Australia, how effective the treatment was, and the variety of treatment options that are implemented if the melanoma recurs.